RECOVEREEZ FORTE - Clinical STUDY

Abstract

Introduction:

Molecular diagnostics using RT-PCR has now emerged as the new diagnostic method for clinicians with the dawn of SARS-CoV-2. In India, the popularity and awareness of RT-PCR and particularly the increased availability of testing machines across hospitals has now opened up possibilities of diagnostic tests with RT-PCR. In view of the cytokine storm which is the significant reason for morbidity and mortality of COVID-19 patients, we proposed to test the usefulness of a multiplex RT-PCR test kit that simultaneously measured inflammatory markers namely, IL-6, TNF– α and IL-10 (IFM) all in one tube. The study included a group of patients who were equally allotted to two treatment arms one of which received standard of care along with a food supplement capsule as a natural anti-inflammatory (RECOVEREEZ FORTE™), and the other group received standard of care that included oral Prednisolone tablets in tapered dosage. RECOVEREEZ FORTE™ consists of potent biomolecules from cardamom extract. A natural product with substantial anti-inflammatory action when consumed early at the onset of symptoms is hereby proven by comparing gene expression profile of inflammatory markers with routinely tested inflammatory parameters such as serum IL-6, CRP and LDH. In addition to predicting worse disease outcomes beforehand, RT-PCR assay tests provides an opportunity for identifying therapeutic window aiding in practicing effective treatment strategy for COVID-19. RT-PCR analysis of IFM together being used in a single multiplex kit is being first reported and such a test as a prognosticator for disease progression does seem promising and worthy of clinicians adopting novel testing modalities in clinical practice.

Aim of the study:

To study the anti-inflammatory response of RECOVEREEZ FORTE™ using RT-PCR based multiplex gene profiling of inflammatory markers in disease prognosis and show its predictability of worsening outcomes and its role in identifying therapeutic window for RECOVEREEZ FORTE™. To show the potentiality of RECOVEREEZ FORTE™ in reducing COVID-19 symptoms and SARS-CoV-2 RT-PCR Ct values of the treatment group. Materials and methods This was a short study of a 10-day period where the end point was the negativity of COVID-19 on RT-PCR test or the decline in cycle threshold (Ct) values of the test performed on day 10 when compared to day 0. During the course of the study, patients were given standard treatment and an oral dose of 500 mg of RECOVEREEZ FORTE™ thrice daily, or standard of care and oral Prednisolone in tapered dosage (control group). All essential interventions were
included in the standard of care as decided by the attending physician. The RT-PCR results of inflammatory markers were compared to routinely tested parameters such as IL-6, CRP and LDH. Time to clinical improvement was in terms of SARSCoV-2 RT-PCR test negativity or recovery of COVID-19 symptoms. We enrolled 64 patients, of which 32 were allocated to RECOVEREEZ FORTE ™ group and 32 to the control group.

Results:

The RT-PCR analysis of elevated IFM on day 0 corresponded to above normal protein levels of routinely tested parameters such as serum IL-6, CRP and LDH on day 5. Similarly, elevated IFM on day 5 corresponded to above normal protein levels on day 10. Such an association was equally prevalent in both the control group and RECOVEREEZ FORTE™ group, stipulating that RECOVEREEZ FORTE™ may be used as an alternative to steroids. The obtained results indicate that the RT-PCR assessment predicts worse outcomes 5 days earlier. But, the RT-PCR analysis of elevated IFM on day 0 did not correspond to the above normal protein levels of other parameters on day 10. Hence, indicating that the IFM RT-PCR test cannot predict worse outcomes 10 days earlier. Also, RECOVEREEZ FORTE™ when consumed for a period of 10 days normalized LDH values, compared to the control group. Moreover, IFM RT-PCR test identified a 5-day therapeutic window for RECOVEREEZ FORTE™ against inflammation experienced by patients. In addition to the above findings, the authors also observed that majority of the patients belonging to the treatment group showed recovery from symptoms such as fever, cough, sore throat and breathlessness compared to control group by day 5. 12 (37.5%) out of 32 patients and 6 (18.75%) out of 32 patients belonging to the treatment group and control group, respectively, became SARS-CoV-2 negative by day 5, indicating a probable anti-viral action of RECOVEREEZ FORTE™ against SARS-CoV-2. Conclusion The IFM RT-PCR test possess 5-day early prediction ability and lacks 10-day prediction ability. Treatment with RECOVEREEZ FORTE™ indicates good anti-inflammatory action which is equivalent to steroids. Intake of RECOVEREEZ FORTE ™ for a period of 5 days depicts persistent anti-inflammatory action, recovery of COVID-19 symptoms and a probable anti-viral action. Moreover, an effective normalization of LDH may be rendered by RECOVEREEZ FORTE™ when consumed for a period of 10 days.

Keywords: COVID-19 · Inflammation · Prognosis · IL-6 · CRP · LDH · Cardamom

Read Full Article
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provokes demanding immune and inflammatory events. Despite numerous reports on the use and testing of several potent therapeutic options against coronavirus disease 2019 (COVID-19), satisfactory treatment has not so far been determined. RECOVEREEZ FORTE TM, consisting of a standardized cardamom extract is a natural product with substantial indications of immunomodulatory and anti-inflammatory actions along with inhibitory capacity averse to viral targets. In this context, we speculated that RECOVEREEZ FORTE TM may ameliorate adverse effects in COVID-19 patients. Accordingly, in a multicenter prospective, open label, randomized trial, adult COVID-19 patients having mild to moderate symptoms were treated with RECOVEREEZ FORTE TM as an adjunct therapy. Patients were assigned to obtain standard of care along with a three times per day oral dose of 500 mg of RECOVEREEZ FORTE TM for ten days, or standard of care alone. Standard of care comprised all essential interventions, as per the discretion of the attending physician. Time to clinical improvement in terms of biochemical parameters such as IL6, CRP, DDIMER, LDH and an RTPCR COVID-19 test negativity in the treated patients was considered to be the primary end point. We enrolled 60 patients; of which 30 were allocated to RECOVEREEZ FORTE TM and 30 to the control group. The duration of COVID-19 positivity post-intervention was significantly shorter in RECOVEREEZ FORTE TM treated group than in the control group (p<0.001). RECOVEREEZ FORTE TM group also showed significant decrease in the levels of IL6, LDH, D-dimer along with increased lymphocytes confirming its immunomodulatory and anti-inflammatory action. We conclude that RECOVEREEZ FORTE TM can reduce the impact of COVID-19 manifestations and could serve as an alternative to oral steroids. We also suggest that RECOVEREEZ FORTE TM may aid faster recovery mediated by its immunomodulatory and anti-inflammatory action in diseases other than COVID-19. The trial was registered in Clinical Trials Registry India (CTRI – CTRI/2021/04/033143) in compliance with the International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use – Good Clinical Practice (ICH–GCP) guidelines.

KEYWORDS: RECOVEREEZ FORTE TM, COVID-19, Anti-inflammatory action, Immunomodulatory action,
Anti-viral Activity, Cardamom extracts

Read Full Article

Recovereez Forte - Non Clinical STUDY Reports

Anti Viral Activity of RECOVEREEZ FORTE in SARS-CoV2 virus

Study Title: Evaluation of Recovereez Forte capsules

Conclusion:

  1. Recovereez Forte capsules exhibited prophylactic activity against SARS-CoV2 when pre-treated with Vero cell line for 1, 2 and 4 hours followed by infection at 0.1 Mol with an ECso value of 46.5 Hg/ml, 34.9 pug/ml and 19.9 pug/ml and Selectivity index (SI) value of o.90,1.20 and 2.10 respectively.
  2. Recovereez Forte capsules exhibited therapeutic activity when treated with cells infected with SARS-CoV2 virus (0.1 Mol) 1 hour, 2 hour and 4 hour post infection with an EC5o value of 20.4 ng/ml, 21.5 pug/ml and 19.3 Hg/ml with a Selectivity index (SI) value of 2.05,1.95 and 2.16 respectively.
  3. Recovereez Forte capsules when incubated with SARS-CoV2 virus (0.1 Mol) for, 2 hour exhibited virucidal activity against SARS-CoV2 with an EC50 value of 1133.0 pug/ml and Selectivity index (SI) value of 0.04.

Interactive Research School for Health Affairs, (IRSHA)
BVDU, Pune-Satara Road, Pure -411043 (INDIA)

View Detailed Report
Anti Viral Activity of RECOVEREEZ FORTE in SARS-CoV2 Delta variant virus

Study Title: Evaluation of Recovereez Forte capsules

Conclusion:

  1. Recovereez Forte capsules exhibited therapeutic activity when treated with cells infected with SARS-CoV2 virus Delta variant (0.1 MoI) 4 hour post infection with an EC50 value of 22.76 µg/ml, with a Selectivity index (SI) value of 1.83.
  2. Recovereez Forte capsules when incubated with SARS-CoV2 virus (0.1 MoI) for, 2 hour exhibited virucidal activity against SARS-CoV2 Delta variant with no trend observed in relative CPE inhibition as increasing concentration of the drug.

Interactive Research School for Health Affairs, (IRSHA)
BVDU, Pune-Satara Road, Pure -411043 (INDIA)

View Detailed Report
Anti-viral Test by CCMB

Anti-viral Testing Report

Specifics of Product: Drug Molecule
Name of the virus tested: SARS-CoV-2

Results:

  1. The molecule showed 75% reduction at 500μg/ml. The viral particle reduced from 106.7 to 106.1

Centre for Cellular and Molecular Biology
Uppal Nagar, Hyderabad – 500007, India

View Detailed Report
Other Study Reports
  1. Acute Oral Toxicity of Recovereez Forte in Rats
  2. RGCB Pseudovirion Assay Report
  3. In Vitro Anti-Inflammatory Action- Test Report
  4. In Vitro Cytotoxicity – Test Report
  5. Evaluation of Recovereez Forte capsules by NIBEC
  6. Molecular Docking – Final Report
  7. Anti-viral Testing Report -CCMB
  8. Acute Oral Toxicity Study Of Recovereez (Capsules) In Wistar Albino Rats
  9. Acute oral toxicity of Recovereez capsules in Wistar rats – Histopathological analysis
View Detailed Reports

References

  1. U.R JUERGENS, U DETHLEFSEN, G STEINKAMP, A GILLISSEN, R REPGES, H VETTER, Anti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial, Respiratory Medicine, Volume 97, Issue 3, 2003, Pages 250-256, ISSN 0954-6111, https://doi.org/10.1053/rmed.2003.1432.
  2. Greiner JF, Müller J, Zeuner MT, Hauser S, Seidel T, Klenke C, Grunwald LM, Schomann T, Widera D, Sudhoff H, Kaltschmidt B. 1, 8-Cineol inhibits nuclear translocation of NF-κB p65 and NF-κB-dependent transcriptional activity. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2013 Dec 1;1833(12):2866-78.
  3. Yu MH, Choi JH, Chae IG, Im HG, Yang SA, More K, Lee IS, Lee J. Suppression of LPS-induced inflammatory activities by Rosmarinus officinalis L. Food chemistry. 2013 Jan 15;136(2):1047-54.
  4. Sengottuvelu S. Cardamom (Elettaria cardamomum Linn. Maton) seeds in health. InNuts and seeds in health and disease prevention 2011 Jan 1 (pp. 285-291). Academic Press.
  5. Al-Sereiti MR, Abu-Amer KM, Sena P. Pharmacology of rosemary (Rosmarinus officinalis Linn.) and its therapeutic potentials.
  6. Hendry ER, Worthington T, Conway BR, Lambert PA. Antimicrobial efficacy of eucalyptus oil and 1, 8-cineole alone and in combination with chlorhexidine digluconate against microorganisms grown in planktonic and biofilm cultures. Journal of antimicrobial chemotherapy. 2009 Dec 1;64(6):1219-25.